Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1809 USD | +7.10% | +2.32% | -83.88% |
05-13 | Earnings Flash (BIOL) BIOLASE Posts Q1 Revenue $10.1M, vs. Street Est of $10M | MT |
04-01 | Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-83.88% | 5.62M | - | ||
+11.29% | 226B | B | ||
+8.76% | 188B | B- | ||
+12.90% | 137B | B- | ||
+25.95% | 108B | A- | ||
+0.34% | 63.19B | A- | ||
+11.08% | 52.26B | B+ | ||
+5.62% | 51B | B+ | ||
+6.28% | 43.89B | A | ||
+4.80% | 38.07B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BIOL Stock
- Ratings BIOLASE, Inc.